C4 Therapeutics (CCCC) director receives 62,000-share stock option award
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
C4 Therapeutics director Stephen Fawell was granted stock options linked to 62,000 shares of common stock. The options carry an exercise price of $4.25 per share and expire on June 23, 2036. This is a compensation-related award, not an open-market purchase.
The option grant vests and becomes exercisable in full on the earlier of June 24, 2027 or the next annual meeting of stockholders, as long as he continues serving on the Board. Following this grant, he holds options covering 62,000 shares directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Fawell Stephen
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 62,000 | $0.00 | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 62,000 shares (Direct, null)
Footnotes (1)
- [object Object]
Key Figures
Option grant size: 62,000 shares
Exercise price: $4.25 per share
Expiration date: June 23, 2036
+2 more
5 metrics
Option grant size
62,000 shares
Stock Option (Right to Buy) underlying common stock
Exercise price
$4.25 per share
Conversion/exercise price of granted options
Expiration date
June 23, 2036
Option term end date
Shares after transaction
62,000 options
Total derivative shares following transaction
Vesting date trigger
June 24, 2027
Earlier of this date or next annual meeting
Key Terms
Stock Option (Right to Buy), exercise price, expiration date, vesting, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
exercise price financial
"conversion_or_exercise_price: 4.2500"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: 2036-06-23T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
vesting financial
"This option shall vest and become exercisable in full upon the earlier to occur of (i) June 24, 2027 and (ii) the next annual meeting"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
Board financial
"subject to the recipient's continued service as a member of the Board on such date"
A board is a group of elected people who oversee a company’s direction and management, like a steering committee that hires and evaluates the CEO, approves major deals, and sets broad policies. Investors care because the board’s decisions and oversight shape strategy, risk, dividend and takeover decisions, and legal protections for shareholders—so a strong, independent board can increase the chances of steady returns and protect against mismanagement.
FAQ
What did Stephen Fawell receive in this C4 Therapeutics (CCCC) Form 4?
Stephen Fawell received a grant of stock options covering 62,000 shares of C4 Therapeutics common stock. These options are a compensation award, not an open-market purchase, and give him the right to buy shares at a fixed exercise price in the future.
What is the exercise price and term of Stephen Fawell’s CCCC stock options?
The granted options have an exercise price of $4.25 per share and expire on June 23, 2036. This long-dated term allows substantial time for potential exercise if vesting conditions are met and Mr. Fawell chooses to exercise.
When do Stephen Fawell’s new C4 Therapeutics options vest?
The options vest and become exercisable in full on the earlier of June 24, 2027 or the next annual meeting of C4 Therapeutics stockholders. Vesting is conditioned on his continued service as a member of the Board through that date.